Glen Santangelo is ranked #1088 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Analyst Tracker/Glen Santangelo

BARC

Glen Santangelo

Q: How accurate are Glen Santangelo's stock ratings?

About 60% of Glen's ratings were profitable over a one-year hold, with an average return of +4.6% per rating, measured by 13Foresight from historical prices.

Barclays

Wall Street Analyst

★★★☆☆

#1088

on 13Foresight · ranked by our own returns

60%

Success Rate

+4.6%

Average Return

59 of 99 calls profitable · -0.6% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 60% of Glen Santangelo's ratings turned a profit when each position was held for 1 year — averaging +4.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

112 Buy 19 Hold 23 Sell

Glen's Stock Coverage 48 ratings · 2026-09-01

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
ANIP ANI Pharmaceuticals	Aug 25, 2026	BUY	Strong Buy +40.0% avg upside 11 analysts	$100.00 36.44% Upside	-3.7%	·
XRAY DENTSPLY SIRONA	Aug 21, 2026	SELL	Buy +159.8% avg upside 25 analysts	$11.00 1.62% Downside	-1.8%	·
DH Definitive Healthcare Corp	Aug 21, 2026	SELL	Hold +470.7% avg upside 19 analysts	$1.00 5.28% Upside	-14.0%	·
ELAN Elanco Animal Health	Aug 21, 2026	BUY	Strong Buy +30.4% avg upside 18 analysts	$30.00 25.39% Upside	+2.2%	·
CTEV Claritev	Aug 20, 2026	BUY	Strong Buy -10.0% avg upside 8 analysts	$40.00 0.34% Upside	+13.8%	·
DOCS Doximity	Aug 20, 2026	HOLD	Buy +35.9% avg upside 28 analysts	$27.00 1.03% Upside	+3.0%	·
GDRX GoodRx Holdings	Aug 20, 2026	SELL	Buy +269.5% avg upside 28 analysts	$4.00 14.68% Upside	+0.8%	·
HIMS Hims & Hers Health	Aug 20, 2026	BUY	Buy -4.7% avg upside 22 analysts	$35.00 18.30% Upside	-10.7%	·
MCK McKesson	Aug 18, 2026	BUY	Strong Buy -13.6% avg upside 29 analysts	$1000.00 13.02% Upside	+2.8%	·
AMPH Amphastar Pharmaceuticals	Aug 18, 2026	HOLD	Hold +15.7% avg upside 11 analysts	$23.00 2.07% Upside	+3.1%	·
CAH Cardinal Health	Aug 18, 2026	BUY	Strong Buy -10.5% avg upside 30 analysts	$275.00 17.15% Upside	-0.1%	·
ZTS Zoetis	Aug 17, 2026	HOLD	Buy +54.0% avg upside 23 analysts	$85.00 10.26% Upside	+5.9%	·
MDLN Medline	Aug 17, 2026	BUY	Strong Buy +33.6% avg upside 27 analysts	$45.00 28.49% Upside	+0.7%	·
NVST Envista Holdings	Aug 17, 2026	BUY	Buy +13.2% avg upside 19 analysts	$32.00 17.95% Upside	-0.7%	·
VTRS Viatris	Aug 17, 2026	BUY	Buy +42.0% avg upside 21 analysts	$22.00 33.15% Upside	+3.6%	·
COR Cencora	Aug 13, 2026	BUY	Buy -1.0% avg upside 45 analysts	$350.00 8.12% Upside	+4.1%	·
TEVA Teva Pharmaceutical	Aug 12, 2026	BUY	Buy -16.4% avg upside 39 analysts	$42.00 16.42% Upside	-1.9%	·
IDXX Idexx Laboratories	Aug 11, 2026	BUY	Buy +31.1% avg upside 17 analysts	$710.00 27.60% Upside	-4.9%	·
WAY Waystar Holding Corp.	Aug 07, 2026	BUY	Strong Buy +42.3% avg upside 30 analysts	$27.00 3.09% Upside	+8.1%	·
ALGN Align Tech	Aug 05, 2026	BUY	Strong Buy +88.3% avg upside 21 analysts	$200.00 25.17% Upside	-8.7%	·
INDV Indivior	Aug 05, 2026	BUY	Strong Buy +7.3% avg upside 10 analysts	$43.00 23.17% Upside	-10.8%	·
HSIC Henry Schein	Aug 05, 2026	BUY	Buy +2.7% avg upside 25 analysts	$100.00 11.29% Upside	+0.8%	·
ALVO Alvotech	Jul 21, 2026	SELL	Buy +51.8% avg upside 7 analysts	$4.00 22.98% Downside	-38.6%	·
PHR Phreesia	Jun 15, 2026	HOLD	Strong Buy +41.3% avg upside 21 analysts	$10.00 18.15% Downside	+29.6%	·
AMRX Amneal Pharmaceuticals	Jun 11, 2026	BUY	Strong Buy +2.9% avg upside 18 analysts	$16.00 8.47% Downside	+8.6%	·
TSE:BHC Bausch Health Companies	Jun 03, 2026	HOLD	Buy +549.0% avg upside 29 analysts	$9.72 10.71% Upside	+26.7%	·
OGN Organon	Feb 24, 2026	SELL	Sell +7.9% avg upside 9 analysts	$8.00 41.78% Downside	-69.5%	·
PGNY Progyny	Jul 21, 2025	BUY	Strong Buy +29.0% avg upside 15 analysts	$29.00 13.35% Upside	+40.5%	·
HQY Healthequity	Jun 12, 2025	BUY	Strong Buy +18.5% avg upside 20 analysts	$130.00 34.68% Upside	-15.0%	·
TDOC Teladoc	Apr 21, 2025	HOLD	Buy +345.7% avg upside 38 analysts	$8.00 26.23% Upside	-7.8%	·
PCRX Pacira Pharmaceuticals	Apr 08, 2025	BUY	Buy +51.1% avg upside 21 analysts	$44.00 69.88% Upside	-11.5%	·
PHAT Phathom Pharmaceuticals	Mar 19, 2025	BUY	Strong Buy +175.5% avg upside 14 analysts	$13.00 35.86% Upside	+83.4%	·
COLL Collegium Pharmaceutical	Mar 17, 2025	BUY	Strong Buy +59.4% avg upside 8 analysts	$40.00 62.45% Upside	+20.4%	·
TARS Tarsus Pharmaceuticals	Mar 06, 2025	BUY	Strong Buy +4.6% avg upside 16 analysts	$58.00 21.95% Downside	+68.1%	·
VRCA Verrica Pharmaceuticals	Jan 06, 2025	BUY	Strong Buy +212.9% avg upside 9 analysts	$30.00 449.50% Upside	+19.4%	·
XERS Xeris Pharmaceuticals	Oct 20, 2022	BUY	Strong Buy +17.8% avg upside 10 analysts	$4.00 52.60% Downside	+40.3%	·
RVLPQ RVL Pharmaceuticals	Oct 20, 2022	HOLD	Strong Buy +624999900.0% avg upside 6 analysts	$2.50 249999900.03% Upside	·	·
SLGL Sol-Gel Technologies	Oct 20, 2022	HOLD	Strong Buy +73.2% avg upside 6 analysts	$5.50 92.11% Downside	-68.1%	·
HCAT Health Catalyst	May 10, 2022	BUY	Buy +232.5% avg upside 15 analysts	$28.00 1607.37% Upside	-23.9%	·
BBLNF Babylon Holdings	Mar 04, 2022	HOLD	Buy +65549900.0% avg upside 6 analysts	$137.50 137499900.04% Upside	·	·
AMWL American Well	Dec 01, 2021	HOLD	Hold +34.4% avg upside 15 analysts	$6.00 49.86% Downside	-39.4%	·
CVS CVS Health	Mar 17, 2021	HOLD	Strong Buy +13.6% avg upside 39 analysts	—	+50.2%	·
SDCCQ SmileDirectClub	Aug 18, 2020	BUY	Sell +382329900.0% avg upside 10 analysts	$10.00 999999900.05% Upside	·	·
AVTR Avantor	Oct 02, 2019	BUY	Buy +8.4% avg upside 26 analysts	$21.00 44.43% Upside	+68.0%	·
DGX Quest Diagnostics	Mar 16, 2016	HOLD	Buy -23.4% avg upside 34 analysts	$72.00 69.98% Downside	+44.6%	·
LH Labcorp Holdings	Mar 16, 2016	BUY	Strong Buy -19.0% avg upside 37 analysts	—	+26.4%	·
ACH Accendra Health	Mar 02, 2016	HOLD	Sell +1304.4% avg upside 17 analysts	—	-4.6%	·
MDRX Veradigm	Nov 07, 2014	BUY	Strong Buy +204.3% avg upside 22 analysts	$15.00 212.39% Upside	+29.2%	·

🔒 43 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Glen Santangelo — Frequently Asked Questions

How accurate are Glen Santangelo's stock ratings?

Based on the calls 13Foresight could measure, about 60% of Glen's ratings were profitable over a one-year hold, with an average return of +4.6% per rating, or -0.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Glen ranked on 13Foresight?

Glen Santangelo is currently ranked #1088 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Glen cover?

Glen most recently has ratings on ANIP, XRAY, DH, ELAN, CTEV, DOCS, GDRX, HIMS, MCK, AMPH, CAH, ZTS and 36 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Glen Santangelo

Rating Distribution

Welcome to 13Foresight!